Steve Harr, Sana CEO
As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies
A unicorn multiple times over, Sana Biotechnology hit Nasdaq running in February with its next-gen cell therapies still months away from the clinic. Now, Sana …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
